Hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder leading to systemic arteriovenous malformations (AVMs), is caused by loss-of-function mutations in the ALK1-ENG-Smad1/5/8 pathway. Evidence suggests that HHT pathogenesis strongly relies on overactivated PI3K-Akt-mTOR and VEGFR2 pathways in endothelial cells (ECs). In the BMP9/10immunoblocked (BMP9/10ib) neonatal mouse model of HHT, we report here that the mTOR inhibitor, sirolimus, and the receptor tyrosine-kinase inhibitor, nintedanib, could synergistically fully block, but also reversed, retinal AVMs to avert retinal bleeding and anemia. Sirolimus plus nintedanib prevented vascular pathology in the oral mucosa, lungs, and liver of the BMP9/10ib mice, as well as significantly reduced gastrointestinal bleeding and anemia in inducible ALK1deficient adult mice. Mechanistically, in vivo in BMP9/10ib mouse ECs, sirolimus and nintedanib blocked the overactivation of mTOR and VEGFR2, respectively. Furthermore, we found that sirolimus activated ALK2-mediated Smad1/5/8 signaling in primary ECs-including in HHT patient blood outgrowth ECs-and partially rescued Smad1/5/8 activity in vivo in BMP9/10ib mouse ECs. These data demonstrate that the combined correction of endothelial Smad1/5/8, mTOR, and VEGFR2 pathways opposes HHT pathogenesis. Repurposing of sirolimus plus nintedanib might provide therapeutic benefit in HHT patients. This study was supported by NIH/NHLBI grants R01HL139778 (to PM) and R01HL128525 (to SPO), DOD/CDMRP grant PR161205 (to SPO and PM), a Feinstein Institutes for Medical Research fund (to PM), Leducq foundation (ATTRACT, to SPO), and Barrow Neurological Foundation (to SPO).
INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant genetic disease with a prevalence of ~1 in 5,000 individuals (1) . HHT is a hemorrhagic vascular dysplasia characterized by the development of mucocutaneous telangiectasias and arteriovenous malformations (AVMs) in multiple tissues and organs. Particularly affected is the vasculature of the liver, lungs, and oronasal and gastrointestinal (GI) mucosa. In its most severe manifestations, HHT can lead to highly debilitating and life-threatening events, such as severe epistaxis and internal bleeding. HHT is also associated with secondary complications, which include anemia, cerebral abscess and embolism following pulmonary AVMs, as well as high-output cardiac failure consecutive to liver AVMs (2, 3) .
At least 85% of HHT patients carry disease-causing loss-of-function mutations in the genes, ENG (encoding endoglin) or ACVRL1 (encoding activin receptor-like kinase 1, ALK1), which define the two disease subtypes: HHT1 (OMIM #187300) and HHT2 (#600376), respectively (4, 5) . Mutations were also reported in SMAD4 (6) (encoding Smad4) and GDF2 (7) (encoding bone morphogenetic protein 9, BMP9), which cause rare and atypical forms of the disease called juvenile polyposis/HHT combined syndrome (OMIM #175050) and HHT-like vascular anomaly syndrome (#615506), respectively. BMP9, ALK1, endoglin, and Smad4 are members of the transforming growth factor-β signaling superfamily and all functionally interact in the same signal transduction axis (8) . The cell surface receptor complex composed of the coreceptor endoglin, the endothelial BMP type I receptor ALK1, and a BMP type II receptor (e.g., BMPR2) is activated by sequential binding to the circulating ligands BMP9 and BMP10 (9) (10) (11) . Mutations in BMPR2 cause familial pulmonary arterial hypertension (PAH), which can be observed in some HHT2 patients (12) , further supporting the notion that ALK1 and BMPR2 functionally interact. ALK1-endoglin receptor activation leads to phosphorylation of the signal transducers, Smad1, Smad5, and Smad8, to trigger the formation of Smad1/5/8-Smad4 complexes that translocate into the nucleus to control specific gene expression programs (13) .
HHT pathogenesis is triggered by a reduction of Smad1/5/8 signaling in ECs. Indeed, HHT-causing mutations decrease Smad1/5/8 response to ALK1-endoglin receptor activation by BMP9 (14) (15) (16) . Consistent with this model, ALK1, endoglin, or Smad4 inactivation in mice and zebrafish leads to vascular defects, which include hypervascularization and AVMs (17) (18) (19) (20) (21) (22) (23) (24) (25) . Downstream from ALK1-endoglin receptor loss-of-function, the exact pathways involved in HHT pathogenesis and ultimately, AVM development-i.e., the formation of direct shunts between an artery and a vein-remain incompletely understood (26). However, concordant studies have shown that HHT is associated with abnormal reactivation of angiogenesis (27) and that overactivated proangiogenic pathways, such as VEGF signaling, are required for the development of the vascular pathology of HHT models (28, 29) . In vitro data in cell cultures have further revealed that VEGFR2 phosphorylation and activity were increased upon ALK1 silencing (30), while endoglin silencing affected VEGFR2 trafficking to increase its downstream signaling (31). Transcriptomic data in ECs have also demonstrated that ALK1 negatively controlled VEGFR2 (KDR gene) expression (32, 33) . In vivo, Vegfr2 knockdown was reported to block hypervascularization and AVMs in Alk1 iΔEC mice (30) and pharmacological inhibition of VEGFR2 reduced disease severity in Eng iΔEC mice (31). Also, recent clinical trials have indicated that intravenous treatment with the VEGF blocking antibody, bevacizumab, provided some therapeutic benefits in severely affected HHT patients (34, 35) . In summary, although the field has not reached a consensus on the exact mechanism by which ALK1-endoglin loss-of-function activates VEGF signaling, there is strong evidence that VEGF-VEGFR2 signaling is a key contributor of the pathogenic process of HHT.
PI3K-Akt overactivation is also involved in AVM development in ALK1 (30) and endoglin (31) deficient mice and in HHT2 patients (36) . Specifically, ribosomal protein S6 (S6) phosphorylation, a downstream effector of mTORC1 and Akt, was reported to be increased in the ECs of AVMs in the Alk1 iΔEC mouse retina and in BMP9-and BMP10-immunoblocked (BMP9/10ib) mice (30), another HHT model. In addition, administration of PI3K inhibitors, such as wortmannin, partially reduced retinal AVM numbers in Alk1 iΔEC , Eng iΔEC , and Smad4 iΔEC mice (25, 30, 31) . Akt1 deficiency also mitigated AVM pathology in the Smad4 iΔEC model (25) . Thus, overactivated VEGFR2 and PI3K-Akt-mTOR pathways are critical drivers-in addition to ALK1endoglin loss-of-function-of HHT pathogenesis and AVM development.
Recently, we (32) and others (37) have reported that tacrolimus (Tac) was associated with Smad1/5/8 signaling activating properties, both in vitro in primary ECs and in vivo in mouse models of HHT and PAH. Spiekerkoetter et al. further reported in a cell-based BMP/Smad transactivation assay and in human pulmonary arterial ECs, that the mTOR inhibitor sirolimus (Siro, rapamycin), a macrolide analog of Tac, also activated Smad1/5/8, although less potently than Tac (37). These data suggest the intriguing possibility that Siro could both prevent mTOR overactivation and rescue Smad1/5/8 signaling in HHT models. In line with this hypothesis, a 2006 case study reported the potential beneficial effect of an immunosuppressive regimen, which contained Siro, in a probable HHT patient who underwent liver transplantation following highoutput cardiac failure and hepatic AVM development (38) . In this patient, the authors observed a reduction in angiodysplasia and mucosal hemorrhage. They proposed that the combination of Siro plus aspirin, in the antirejection regimen, could have contributed to the observed effects in this HHT patient (38).
Several receptor tyrosine kinase (RTK) inhibitors that target VEGFR2 are FDA/EMAapproved, including pazopanib that showed beneficial effects in ALK1 deficient mice (39) and in a cohort of HHT patients (40) . A recent case study reported that nintedanib (Nin, BIBF 1120), another VEGFR2-targeting RTK inhibitor, which is approved for idiopathic pulmonary fibrosis (IPF) treatment, produced marked reductions in epistaxis and skin telangiectasias in a patient affected by both HHT and IPF (41) . Nin is of particular interest compared to other classical RTK inhibitors because it has a narrow spectrum of inhibition and is associated with minimal adverse effects.
In this context and in the current study, we sought to determine whether concurrent pharmacological targeting of Smad1/5/8 reduction, and of mTOR and VEGFR2 activation, could rescue the signaling defects and vascular pathology of HHT. We report that Siro and Nin, when administered in combination, mechanistically synergize at the transcriptional and signaling levels to efficiently prevent and reverse the vascular pathology, and the associated bleeding and anemia, in two HHT mouse models.
RESULTS

Sirolimus and nintedanib combination prevents vein dilation, hypervascularization, and AVM development in the retina of the tBMP9/10ib mice.
Recently, we have reported the development of a HHT mouse model, which uses the transmammary route for administering BMP9 and BMP10 blocking antibodies to nursing mouse pups (22, 32) , hereafter referred to as the transmammary-treated BMP9/10 immunoblocked (tBMP9/10ib) mice. We showed that this model, which has the advantage of being less invasive for the pups and more suitable for the analysis of large cohorts, leads to reduced ALK1 signaling and the development of a robust HHT-like pathology in the retinal vasculature of the pups (22, 32) . In this model, we found that Tac significantly activated endothelial ALK1 signaling in vivo and prevented hypervascularization of the tBMP9/10ib retina. Further analyses of Tac efficacy in preventing vascular pathology in tBMP9/10ib mice revealed, however, a relatively modest effect of the drug on AVM development (32). These data prompted us to determine whether the macrolide analog of Tac, Siro (administered alone and in combination with Nin), is more potent in reducing the vascular pathology of the tBMP9/10ib retina.
Studies were conducted prior to these experiments to determine the appropriate dosing and injection schedule of the drugs in pups. The highest dose of Siro that did not affect normal vascular development was chosen [0.5 mg/kg, intraperitoneal (i.p.) injection of the pups, assessed in the neonatal retina]. Similarly, in order to prevent changes in retinal vascular development, we determined that Nin should be given every third day and not before P5. With this schedule for Nin injection, the highest dose of the drug that did not affect physiological vascular development was determined to be 0.3 mg/kg (i.p., data not shown). Co-administration of Siro and Nin (Siro+Nin) at these dosing and injection schedules did not also significantly affect normal vascular growth, indicating that physiological angiogenesis in the retina was not inhibited by the drug combination ( Figure S1 ). At this dosing, LC-MS analyses measured average serum concentrations of 9.0 nM Siro and 5.3 nM Nin in the injected P6 pups.
As shown in Figure 1A and described before (22, 32) , vascular pathology in pups was initiated at postnatal day 3 (P3) by one i.p. injection of the dams with anti-BMP9/10 antibodies. Mouse pups were administered preventively and daily with Siro from P3 to P5 (0.5 mg/kg, i.p.) and with Nin at P5 (0.3 mg/kg, i.p.). Mice were then analyzed at P6 ( Figure 1A ), a time point at which retinal vessel dilation, hypervascularization, and AVMs can readily be observed and quantified in this model (22, 32) . In the tBMP9/10ib retinas, Siro significantly reduced AVM number and AVM diameter ( Figures 1B-1D , 1G-1I, 1Q, and 1R). In addition, as we observed previously for Tac at the same dosing (0.5 mg/kg, P3-P5, i.p.) (32), Siro prevented vein dilation ( Figure 1S ) and the increase in density of the vascular plexus ( Figures 1B-1D , 1L-1N, and 1T). In contrast, Nin at the tested dosing failed to reduce any of the investigated vascular defects of the tBMP9/10ib retinas ( Figures 1B, 1C , 1E, 1G, 1H, 1J, 1L, 1M, 1O, and 1Q-1T).
Although Siro treatment was able to significantly reduce AVM number and size, its preventive effect was only partial (AVM number, mean = 3.79 ± 0.30 in DMSO-treated tBMP9/10ib retinas vs. mean = 1.57 ± 0.19 in Siro-treated tBMP9/10ib retinas, P≤0.01). Knowing that evidence is strong to suggest that VEGFR2 signaling is increased in HHT models and that Siro demonstrated no efficacy in inhibiting VEGFR2-mediated MAPK signaling activation in primary ECs [ Figure S2 and Ref. (42) ], we asked whether the VEGFR2 inhibitor Nin could increase Siro potency in preventing AVMs. Combination treatment with the two drugs resulted in a significant increase of Siro anti-AVM effect (Figures 1B-1K and 1Q; AVM number after treatment, mean = 0.35 ± 0.11, P≤0.0001 vs. DMSO-treated tBMP9/10ib retinas, and P≤0.05 vs. Siro-treated tBMP9/10ib retinas). Siro+Nin combination did not further increase the effect of Siro on vein dilation and vascular density, as Siro alone was sufficient to fully correct these two defects ( Figures 1L-1P , 1S, and 1T). Measurement of the diameter of the few remaining AVMs identified in the retina of the Siro+Nin-treated mice also revealed no difference compared to treatment with Siro alone ( Figure 1R ). Together these data in tBMP9/10ib mice show that Siro fully normalized vein dilation and hypervascularization, and significantly lowered AVM number and size in the retina. Furthermore and more strikingly, Nin significantly strengthened the anti-AVM effect of Siro.
Siro+Nin prevents anemia and retinal bleeding in tBMP9/10ib mice.
We next assessed pathology progression in tBMP9/10ib pups at P9. As before, vascular pathology in pups was initiated at P3 by one i.p. injection of the dams with anti-BMP9/10 antibodies ( Figure  2A ). Complete blood count (CBC) revealed significant reductions in hematocrit level, red blood cell (RBC) number, and hemoglobin level ( Figure 2B ), indicative of anemia in P9 tBMP9/10ib pups. Furthermore, severe cardiomegaly (Figures 2C and 2D) and splenomegaly ( Figure 2C ) developed in tBMP9/10ib mice. Splenomegaly was accompanied by an expansion of the red pulp ( Figure 2D , right panels), indicating the presence of splenic erythropoietic stress response consecutive to anemia. These data prompted us to investigate whether tBMP9/10ib mice were actively bleeding. Inspection of the retinas using whole-mount immunohistochemistry (IHC) with an antibody directed against the RBC marker, Ter119, revealed the presence of strongly immunoreactive patches in multiple areas of the tBMP9/10ib retinas (Figures 2E, 2F , and 2K). Single-cell resolution confocal analyses and 3D reconstruction showed the presence of RBC patches outside the tBMP9/10ib retinal vasculature (Figures 2H-2H" and 2I-2I", and animation in Movie S1). Interestingly, isolectin B4-positive projections could clearly be identified near the center of some of these RBC accumulations, suggesting that they might represent transversal vascular projections at the origin of the bleeding (Figures 2I-2I", arrows; Movie S1). Treatment of the tBMP9/10ib mice with Siro+Nin from P3 to P8 (Figure 2A ) significantly reduced the area occupied by retinal bleeding (Figures 2E-2K ) and fully prevented the decrease in hematocrit level, RBC number, and hemoglobin level ( Figure 2B ), as well as blocked cardiomegaly, splenomegaly, and the loss of splenic architecture ( Figures 2C and 2D ). Thus, Siro+Nin combination treatment prevented anemia and retinal bleeding in tBMP9/10ib mice.
Because evidence is mounting that AVM development is controlled by blood flow (43) and because P9 tBMP9/10ib mice display significant cardiomegaly, we asked: (i) whether tBMP9/10ib mice develop cardiac defects leading to higher cardiac output and (ii) whether the drugs could indirectly reduce vascular pathology by correcting these cardiac defects. Although a modest decrease in heart rate was measured by doppler ultrasonography upon drug treatment in tBMP9/10ib mice, heart rate was overall not significantly changed in DMSO-treated and Siro+Nin-treated tBMP9/10ib pups, compared to normal pups ( Figure S3A ). In addition, no significant defects in cardiac output ( Figure S3B ) or pulmonary arterial pressure ( Figure S3C ) measures were found between all groups. These data demonstrate that basic cardiac function is normal in tBMP9/10ib pups, at least until P9, and that Siro+Nin combination is therefore unlikely to act on the vasculature by changing cardiac output.
Siro+Nin reverses vascular pathology in tBMP9/10ib mice.
We next analyzed the retinal vasculature of P9 tBMP9/10ib mice treated or not with Siro+Nin. On average ~4 AVMs were detected in tBMP9/10ib mice ( Figures 2L and S4 ), indicating that no additional AVMs developed between P6 (mean = 3.79 ± 0.30, Figure 1Q ) and P9. Strikingly, while Siro+Nin-treated P6 mice still contained some AVMs (n = 0.35 ± 0.11, Figure 1Q ), the P9 tBMP9/10ib mouse retinas that were treated with the drugs for 3 additional days were devoid of AVMs ( Figures 2L and S4 ). In addition, the 6-day-Siro+Nin treatment (P3-P8, Figure 2A ), as we observed after the 3-day-Siro+Nin treatment (P3-P5, Figure 1 ), fully prevented vein dilation and hypervascularization ( Figures 2L and S4 ). LC-MS analyses measured an increase in average drug concentrations in the pup serum between P6 and P9: from 9.0 nM to 22.6 nM Siro and from 5.3 nM to 24.7 nM Nin, indicating that three additional days of drug treatment led to an accumulation of the drugs in the circulation.
These data suggest that Siro+Nin treatment might also reverse existing AVMs, since some AVMs disappeared between P6 and P9. To directly address this possibility, we implemented a protocol that started the drug treatment once retinal vascular pathology was established. Specifically, pathology was induced as before at P3 and pups were then treated at P6 with Siro+Nin, a time point where we have established the presence of robust vein dilation, hypervascularization, and of ~4 AVMs per retina ( Figure 1 ). Pups were treated for 3 days, from P6 to P8 (P6-P8), and analyzed at P9 ( Figure 3A ). We found that Siro+Nin administered after pathology induction significantly reduced overall vascular pathology ( Figure S5 ), including AVM number, AVM size, vein dilation, and vascular density ( Figures 3B and 3C ). In addition, P6-P8 Siro+Nin treatment significantly increased hematocrit level, RBC number, and hemoglobin level in anemic tBMP9/10ib mice ( Figure 2B ).
Since disease induction is triggered by only one i.p. injection at P3 of anti-BMP9/10 antibodies, we verified that the observed effects of Siro+Nin in P9 pups were not facilitated by a disappearance of the disease-causing anti-BMP9/10 blocking antibodies from the pup circulation. Using specific anti-BMP9 and anti-BMP10 antibody ELISAs, we found that serum antibody concentrations were stable between P6 and P9, and reached ~70 µg/mL for the anti-BMP9 antibody and ~85 µg/mL for the anti-BMP10 antibody ( Figure S6 ). Thus, the disease-causing effects of the anti-BMP9/10 antibodies was maintained between P6 and P9, and therefore, the drug combination effect on pre-existing AVMs occurred in a maintained pathogenic environment. Taken together, these findings demonstrate that Siro+Nin combination treatment not only prevented, but also reversed, the retinal vascular pathology of the tBMP9/10ib mice.
Siro+Nin prevents vascular pathology in the oral mucosa and lungs of the tBMP9/10ib mice.
The oral mucosa and lungs are major sites of vascular lesion development in HHT patients. We investigated whether vascular defects are observed in these tissues of the P9 tBMP9/10ib mice. Injections of latex blue dye in the blood circulation were used to visualize vascular pathology. In the tBMP9/10ib mouse tongue and palate, mucosal vein dilation and hyperproliferative vascular defects were clearly identified after latex dye injection ( Figures 4A, 4B , 4D, and 4E). Significant enlargements of the lingual and greater palatine vessels could be measured, compared to control tongues and palates ( Figure 4J ). In the lungs, the dye invaded a hypervascularized network of dilated small vessels throughout the lobar system and revealed an enlargement of the main pulmonary vessels of the tBMP9/10ib mice (Figures 4G, 4H, and 4J). Siro+Nin treatment of the tBMP9/10ib mice significantly and efficiently prevented the hyperproliferative vascular pathology and vessel dilation phenotype observed in the tongue, palate mucosa, and lungs ( Figure 4 ). Thus, Siro+Nin combination reduced vascular pathology in the oral mucosa and lungs.
Siro+Nin corrects a gene expression signature and prevents vascular pathology in the liver of the tBMP9/10ib mice.
The liver is the most vascularized organ of the body and is a major site of vascular lesion development in HHT patients, more specifically in HHT2 patients (44) . We next investigated whether vascular defects could be observed in the liver of the P9 tBMP9/10ib mice. Vascular pathology induction and drug treatments in pups were performed as above ( Figure 2A ). Latex dye tissue invasion was enhanced in the tBMP9/10ib liver and revealed a significant enlargement of the hepatic vessels (Figures 5A, 5B, and 5D). Hematoxylin and eosin (H&E) staining showed the presence of marked local liver injury, characterized by the presence of significant hepatocyte vacuolation and hepatocellular necrosis (Figures 5E, 5F, 5H, 5I, and S7), a pathology that could result from ischemic events.
To gain insight into the mechanism of liver injury, we performed a proteome array for angiogenesis-related factors. This screen identified plasminogen activator inhibitor 1 (PAI-1) as a protein strongly upregulated in the tBMP9/10ib liver, compared to livers from control mice ( Figure  5K ). PAI-1 is of interest because it is upregulated during hypoxia (45) , and might thus represent a response to ischemia. PAI-1 elevation in the tBMP9/10ib liver was confirmed by Western blot (WB, Figure 5L ) and IHC ( Figures 5M, 5N , and 5P) analyses. To verify that hypoxia is occurring in the tBMP9/10ib liver, tissue sections were stained for hypoxia-inducible factor-1α (HIF-1α), a transcriptional factor marker and master regulator of hypoxia (46) . We found a strong upregulation of liver HIF-1α expression in tBMP9/10ib mice, compared to control mice (Figures 5Q, 5R, and 5T). These data show that tBMP9/10ib mice develop a robust vascular pathology in the liver. Strikingly, Siro+Nin treatment of the tBMP9/10ib mice significantly prevented the hyperproliferative vascular pathology and vessel dilation phenotype of the liver ( Figures 5A-5D ). In addition, Siro+Nin efficiently reduced hepatocyte vacuolation and necrosis (Figures 5E-5J and S7), as well as prevented the overexpression of PAI-1 and HIF-1α in the liver of the tBMP9/10ib mice ( Figures 5M-5T ). Together, these results demonstrate that Siro+Nin combination prevented vascular pathology in the liver, as well as blocked liver disease in tBMP9/10ib mice.
To further test the therapeutic potential of the Siro+Nin combination, we determined: (1) whether gene expression changes could be detected in the tBMP9/10ib whole-liver tissue and (2) whether treatments with the two drugs (administered alone or in combination) could correct these transcriptomic changes. When we plotted the transcript expression changes (measured as log fold change values, logFC) in tBMP9/10ib pups vs. normal controls, against the transcript expression logFCs obtained after treating the tBMP9/10ib pups with Siro+Nin vs. vehicle (DMSO), an inverse correlation was found for Siro+Nin treatment (r 2 = 0.380, P<0.001; Figure 6A ). An inverse correlation indicates that Siro+Nin treatment normalized some of the changes observed in the disease model (tBMP9/10ib pups) compared to normal controls. When the same comparison was done for Siro and Nin administered alone, a weaker correlation was measured (r 2 = 0.193 and 0.190, respectively, P<0.001; Figure 6A ). These results indicate that Siro+Nin combination better corrected the expression changes of liver transcripts detected in the tBMP9/10ib mice, than either drug administered alone.
To illustrate the synergistic effect of the Siro and Nin treatments on transcript expression, we identified transcripts that were differentially changed by the drug treatments in the tBMP9/10ib liver (n = 6-9 biological replicates/group, false discovery rate (FDR) ≤0.5%, log average expression >-5; Figure 6B ). These transcripts are shown in Figure S8 and Table S1 . The black box in the heatmap of Figure 6B shows a subset of transcripts that were: (1) significantly changed by Siro+Nin, (2) not changed by either Nin or Siro administered in isolation, and (3) whose expression was normalized, as compared to normal controls. This subset of transcripts confirms that a synergistic effect exists between Siro and Nin treatments at the gene expression level, and that this effect could normalize a subset of deregulated transcripts in the tBMP9/10ib liver. A function enrichment analysis of the identified subset of normalized transcripts revealed a significant network of genes involved in cell and protein metabolism (e.g., Uba6, Tmem56, mt-Nd3, Kdm1b, Gclc, Prkd3; GeneMANIA (47)), a response indicative of strong gene expression changes consecutive to liver injury and changes in cell homeostasis and cell stress.
Together, these transcriptomic data show that Siro and Nin treatments synergized and partially opposed a deregulated gene expression signature detected in the tBMP9/10ib liver. These results are important because they confirm the interaction and combination efficacy of the two drugs in reducing overall vascular pathology in tBMP9/10ib mice. 
Siro+Nin reduces GI bleeding and anemia in adult
In tBMP9/10ib mice, Siro and Nin prevent endothelial overactivation of mTOR and VEGFR2, respectively.
We next assessed mTOR signaling in tBMP9/10ib mice by measuring the levels of phospho-mTOR (p-mTOR) and phospho-S6 (p-S6) in the liver and retina. WB analyses revealed robust increases in p-mTOR and p-S6 levels in whole-liver homogenates isolated from tBMP9/10ib mice, compared to control mice ( Figure 8A ). Treatment with Siro (alone or in combination with Nin) blocked S6 phosphorylation and normalized p-mTOR levels in the tBMP9/10ib mouse liver ( Figures 8A and S9 ). Further examination of the tBMP9/10ib retinal tissue confirmed the presence of strong p-S6 immunoreactivity in the AVMs, which could significantly be blocked by Siro treatment of the mice ( Figures 8B and 8C) .
A significant elevation of activated phospho-VEGFR2 (p-VEGFR2) was detected in protein homogenates of liver ECs isolated from tBMP9/10ib mice (Figures 8D and S10) and in the tBMP9/10ib mouse retina ( Figure 8E ), which was significantly inhibited by Nin treatment of the mice ( Figures 8D-8F ). We also verified that drug combination did not interfere with the inhibitory effect of Nin on p-VEGFR2. As observed upon treatment with Nin alone, Siro+Nin fully inhibited VEGF-induced VEGFR2 activation in primary ECs ( Figure S2 ). Altogether, these data confirmed that endothelial mTOR and VEGFR2 are overactivated in tBMP9/10ib mice and that Siro and Nin can respectively and efficiently block these signaling deregulations in vivo.
Siro rescues Smad1/5/8 signaling by activating ALK2.
Because the possibility that Siro might both prevent mTOR overactivation and rescue Smad1/5/8 signaling in HHT mice is appealing, we revisited the effect of Siro on Smad1/5/8 signaling in cell culture systems. We found that Siro increased Smad1/5/8 phosphorylation (p-Smad1/5/8) in a dose-dependent manner and increased the levels of the Smad1/5/8 downstream target ID1 (inhibitor of differentiation 1) in C2C12 myoblast cells ( Figure S11A ) and in human umbilical vein ECs (HUVECs, Figure 9A ), at doses very comparable to Tac (32). A pharmacological approach using the pan-ALK inhibitor LDN-193189 ( Figure 9B ) and gene silencing (Figures 9C and S11B) in HUVECs further showed that ALK2 is required for the stimulatory effect of Siro on Smad1/5/8 signaling.
To further demonstrate efficacy in a cell culture system more directly relevant to the pathophysiology of human HHT, we used blood outgrowth ECs (BOECs) isolated from a HHT2 patient genetically confirmed to carry the disease-causing ALK1 T372fsX truncation (32). Treating these HHT2 patient BOECs with Siro also increased p-Smad1/5/8 and ID1 levels ( Figure  9D ). Finally, IHC analyses showed that in vivo Siro was able to modestly but significantly rescue the decrease of p-Smad1/5/8 in the retinal vasculature ( Figures 9E and 9F ). Thus, Siro displayed potent in vitro Smad1/5/8 signaling activating properties in EC cultures, including in HHT patientderived ECs, and significantly rescued Smad1/5/8 loss-of-function in vivo in tBMP9/10ib mice.
DISCUSSION
Major progress in techniques of interventional radiology, embolization, and cauterization have considerably reduced the risk of hemorrhage in HHT patients. However, the recurring and progressive nature of the disease continues to make HHT a highly debilitating disorder associated with life-threatening sequelae. Several disease-modifying therapies have been proposed in preclinical models and some of them are currently being investigated in clinical trials (49) . Notably, Tac was found to be associated with Smad1/5/8 activating properties in ECs and showed some efficacy in reducing pathology in HHT (32) and PAH (37) models and patients (50) (51) (52) . Here we propose that Siro, a structural analog of Tac and inhibitor of mTOR, is a more potent blocker of AVM development in HHT mice. We found that Siro acts as a dual modulator by stimulating Smad1/5/8 while inhibiting mTOR, in both cell cultures and HHT mice, thus correcting two key signaling defects of the HHT ECs.
In cell cultures, Tac was proposed to activate Smad1/5 by facilitating dissociation of the binding repressor FKBP12 from ALK1, ALK2, and ALK3, while Siro only recruited ALK2 (37). Here we confirmed in HUVECs that Siro could activate endothelial Smad1/5/8 by specifically stimulating ALK2. Although these data would need to be confirmed in vivo, they suggest that the intriguing possibility that ALK2 activation might compensate for ALK1 loss-of-function. Although attractive from a mechanistic aspect, this mechanism might be risky as ALK2 activating mutations are associated with fibrodysplasia ossificans progressiva, a disorder characterized by progressive heterotopic bone formation in muscle tissues (53) . However, Siro, as well as Tac that also activates ALK2, are not known to lead to any adverse effects associated with mechanisms of abnormal ossification in humans. In addition, Siro showed a potent anti-AVM effect at doses (9-22 nM in mouse serum) comparable to its use in the clinical setting (whole-blood trough concentrations of ~15-20 nM for prophylaxis of transplant rejection, for instance).
Our data highlight a beneficial interaction and synergy between Siro and Nin treatments in HHT mice. This interaction was observed by RNA-Seq of the tBMP9/10ib liver, which revealed the presence of deregulated genes that were fully normalized only when Siro and Nin were coadministered. This transcriptional interaction translated into a robust synergy of the two drug treatments and a significant improvement of the Siro effect at preventing AVMs in HHT mice. We found that Nin acted, at least in part, by blocking the overactivation of VEGFR2 in ECs of the tBMP9/10ib mice. Nin is not specific to VEGFRs, as it also targets FGFRs and PDGFRs, two other receptor families involved in angiogenesis (54) . Further investigation will be needed to determine whether interference of these other RTK receptor pathways might be involved in the anti-AVM effect of the Siro+Nin combination. Previous work suggests, however, that this might not be the case for PDGFRs, since PDGF signaling activation (not inhibition) was found to mitigate vessel wall defects in an Eng KO mouse model (55) .
The current data provide further evidence that HHT pathogenesis requires the overactivation of the mTOR and VEGFR2 pathways ( Figure 9G ). How Smad1/5/8, mTOR, and VEGFR2 control each other during the disease process remains unclear. Although loss-of-function mutations in BMP9-ALK1-endoglin-Smad4 signaling are necessary to cause HHT, they are not sufficient. Indeed, additional genetic, environmental, and/or developmental modifiers are required for AVM development, a process referred to as the double/multiple hit hypothesis (56) . Notably, VEGF stimulation or wounding, two triggers of angiogenesis, were reported to be required to generate brain and skin AVMs in adult ALK1 deficient mice (43) . Furthermore, in HHT neonate mouse models, including in tBMP9/10ib pups, it is believed that retinal AVMs develop spontaneously and aggressively because vessel development is actively occurring through angiogenesis. Synergy between BMP9/10 blocking and VEGFR2 activation during the normal process of angiogenic vascular development would thus provide in these models the ideal milieu for lesion development. Therefore, although there is now strong evidence that Smad1/5/8 reduction overactivates VEGF signaling to cause vascular pathology, these two pathways are initiated by independent triggers. Our data showing that Nin and Siro treatments have clear synergistic effects support this notion and further show that the two pathways can independently signal in ECs to cause AVMs.
Recent studies have demonstrated that PI3K-Akt signaling is overactivated in several HHT models and that its inhibition reduces the AVMs (25, 30, 31) . In line with this observation, we show here that, in the tBMP9/10ib liver, there is an increase of p-Ser 2448 -mTOR, a phosphorylation mostly associated with mTORC1, the mTOR complex downstream from PI3K-Akt, which is directly targeted by Siro (57) . In addition, Siro treatment, which fully prevented p-Ser 2448 -mTOR and S6 overactivation, reduced AVM number in our model, suggesting that mTOR, most likely downstream from PI3K-Akt, is a major player in AVM development. We further found that, although Siro fully inhibited mTOR overactivation in vivo, its anti-AVM effect was only partial and could be significantly potentiated upon VEGFR2 inhibition by Nin, indicating that VEGFR2 can signal independently of the PI3K-Akt-mTOR pathway to control the AVMs. This observation concurs with recent data obtained in Smad4 deficient mice that indicate that abnormal PI3K-Akt activation in ECs is primary controlled by blood flow and not VEGFR2 (24, 58) .
An important question relates to the drug dosing used in this study and whether it allows the administered drugs to reach concentrations within the expected therapeutic range. We measured in average 9.0 nM Siro and 5.3 nM Nin at P6, and an increase to 22.6 nM Siro and 24.7 nM Nin at P9 in the pup serum. Previously published in vitro experiments reported a Siro IC50 of ~0.1 nM for mTOR (59) and a Nin IC50 of ~13 nM for VEGFR2 (60) . At the tested dosing, circulating concentrations of Siro and Nin are therefore expected to inhibit in vivo mTOR and VEGFR2, which is in line with the observed effects on these targets in tBMP9/10ib mice ( Figure  8 ). For Smad1/5/8 stimulation by Siro, our experiments in HUVECs showed that the lowest effective concentration is 100 nM ( Figure 9A) , which is about 4 times higher than the concentration detected in the serum. We found nonetheless that Siro treatment modestly but significantly increased p-Smad1/5/8 in the mouse retina, indicating that the drug was delivered in sufficient quantities to stimulate Smad1/5/8 signaling in vivo ( Figure 9 ). We have not obtained clear experimental data that explain this apparent discrepancy. However, it is important to note that concentrations used in vitro and drug serum concentrations are difficult to compare. Indeed, drug concentration measurements in the circulation do not consider the pharmacokinetic and bioavailability of the drugs. One important parameter is cellular uptake and accumulation, which can significantly reduce serum concentration while increasing local drug delivery. Altogether these data suggest that the administered drugs reach concentrations within the expected therapeutic range.
We found that Siro+Nin treatment prevented anemia in P9 tBMP9/10ib pups and adult Alk1 iKO mice (Figures 2B and 7D-G) . In tBMP9/10ib pups, drug treatment generated a supranormal elevation of the CBC parameters. In some models of anemia, Siro was reported to ameliorate anemia by increasing stress erythropoiesis (61) . In this context, the supranormal elevation of the CBC parameters measured after drug treatment could be due, in part, to changes in erythropoiesis. To test this hypothesis, additional experiments were performed by using the recently described method of monitoring erythropoiesis using CD44/Ter119/FSC as markers of terminal erythroid differentiation (62) . We measured a significant increase in the number of reticulocytes in the bone marrow, but not in the spleen, of Siro+Nin-treated tBMP9/10ib mice ( Figure S12 ). These data suggest that although no stress erythropoiesis induction was observed, an increase in RBC production occurred and thus could explain, at least partly, the supranormal levels of hematocrit, RBCs, and hemoglobin measured after the drug treatment. Further investigation will be required to clearly define the origin of the observed effects, for instance, by looking at the earlier RBC precursors (62) . Other experiments will also be needed to precisely determine how much of the corrected anemia is driven by a bleeding reduction ( Figure 2K) vs. an increased RBC production ( Figure S12 ) and whether the drug effect on RBC production could be related to developmental aspects in newborn mice. In support to the latter possibility, a supranormal elevation of the RBC counts was not found in treated adult Alk1 iKO mice (Figure 7) , further supporting our current interpretation that anemia correction is primarily driven by a bleeding reduction.
Prophylaxis of rejection in liver transplantation includes treatment with immunosuppressive drugs, primarily Tac and more rarely Siro. Recently, liver AVM pathology recurrence was reported in HHT patients who underwent liver transplantation, while they were treated with Tac (63). Our study suggests the possibility that prioritizing Siro vs. Tac (together or not with Nin) in the antirejection regimen might also help in specifically preventing spreading of vascular disease in healthy liver grafts.
More broadly, the beneficial effect of Siro and mTOR inhibition has already been described in models of pathological angiogenesis (64) . In addition, Siro treatment has produced promising results in patients affected by vascular anomalies (65) . Our observation that Siro and Nin mechanistically synergize to block the pathogenic process of HHT might thus have important ramifications for the treatment of other vascular disorders, such as the vascular anomaly diseases.
In conclusion, the present data show that Siro and Nin combination concurrently normalizes endothelial Smad1/5/8, mTOR, and VEGFR2 pathways to synergistically and efficiently oppose HHT pathogenesis and the associated vascular pathology in neonate and adult mouse models of the disease. We thus propose that Siro+Nin combination has therapeutic potential in HHT.
METHODS
Mice.
This study was performed using C57BL/6 mice (The Jackson Laboratory). R26Cre ER/+ ;Alk1 2f/2f mice generation and Alk1 deletion using tamoxifen were described previously (39, 48). Mice were maintained in regular housing conditions and were allowed free access to water and maintenance diet.
Transmammary-delivered immunoblocking of BMP9 and BMP10, and drug treatments.
tBMP9/10ib pups and age-matched control pups (treated with isotype controls) were generated as previously described (22, 32) . Pups (litter size, n = 7-9 mice; average mouse weight, 2 grams) were treated with vehicle (0.1% DMSO in saline), Siro (0.5 mg/kg bw), and Nin (0.3 mg/kg bw) following the different combinations and schedules described in the Figures. Isotype control pups were injected with vehicle. 
RNA-Seq, read alignments, and gene expression differential expression analysis. RNA was
Figure 6. Siro+Nin corrects a gene expression signature detected in the tBMP9/10ib mouse liver. (A)
Scatter plots comparing the liver gene expression changes (logFC, log fold change) observed upon treatment with Siro+Nin or individual drug (Siro or Nin), to the liver gene expression logFCs observed between tBMP9/10ib and normal control (CTRL) mice. The negative slope of the plots indicates that each treatment contributed to normalize the liver gene expression changes seen in tBMP9/10ib vs. CTRL mice. Correlation coefficients (r 2 ) indicate a more robust normalization with the drug combination than with individual drugs. (B) Heatmap of liver transcripts synergistically differentially expressed by the drug combination. We identified the genes that responded to the drug combination differently than would be expected assuming an additive effect of both drugs. Non-interacting drug would produce a COMBO expression equal to the average of gene expression measured with each treatment (NIN or SIRO). The significant effects that we detected, measured with the statistical contrast COMBO-(NIN+SIRO)/2, produced gene expression changes that deviate from this average independent effect expectation. Transcripts were selected with FDR≤0.5%, log average expression >-5. For reference, liver transcripts in CTRL mice are shown on the heatmap. Gene expression in CTRL mice were used for normalization, but were not used in the selected transcripts that displayed synergistic drug response. Figure 1A . Data show the % of total retinal length occupied by the vasculature and represent mean ± SEM (n = 6, 4, 5 mice for the non-treated, DMSO, and Siro+Nin groups, respectively). One-way ANOVA and Tukey's multiple comparison tests revealed no significant difference between groups. Figure S6 . Transmammary-delivered BMP9 and BMP10 blocking antibodies persist in the circulation of mouse neonates. ELISAs were performed to measure anti-BMP9 (A) and anti-BMP10 (B) IgG concentration in the serum of P6 and P9 pups treated either at P3-P5 or P3-P8 through lactation from dams injected i.p. with PBS, isotype controls (IgG2a/b), or anti-BMP9 + anti-BMP10 antibodies (anti-BMP9+10). Data represent mean ± SEM (n = 6 and 5 mice for the P6 and P9 groups, respectively). One-way ANOVA and Tukey's multiple comparison tests revealed no significant difference between P6 and P9 mice for the anti-BMP9+10 groups. Figure 2A . Liver histological evaluation was performed according to the standardized semi-quantitative scoring system previously described (1) . Data represent the mean of means ± SEM (5 random images of the liver per mouse, n = 3, 4, 4 mice for the CTRL, DMSO, and Siro+Nin groups, respectively); Kluskal-Wallis test, Dunn's multiple comparison test; ***P<0.001,****P<0.0001. Figure 6 . The plot shows that the normalization and covariate adjustments employed were adequate for this dataset (most genes lie on a horizontal line corresponding to no change in gene expression with, as expected, more spread along the vertical for genes measured with low expression). Genes detected significant with a FDR≤1% are shown in red. Figure 2A with DMSO or Siro+Nin, and based on the expression levels of CD44 and Ter119, as described in (2) . Data represent the mean of means ± SEM (n = 3 and 4 mice for the DMSO and Siro+Nin groups, respectively); two-way ANOVA, Bonferroni's multiple comparison test; **P<0.01. SUPPLEMENTAL TABLE LEGENDS   Table S1 . Transcripts differentially expressed upon synergistic drug treatment. Transcripts shown in the heatmap of Figure 6 are presented in table form. Selection was the same as the heatmap: FDR≤0.5%, log average expression >-5. The transcripts were annotated with Biomart and ensembl genes 94 annotations.
SUPPLEMENTAL METHODS
Reagents and antibodies. BMP9 (3209-BP) and VEGF165 (293-VE) were obtained R&D Systems. Sirolimus (Siro, S1039), nintedanib (Nin, S1010), and LDN-193189 
Measurements of antibody levels by ELISA in neonatal mouse serum.
ELISAs were performed as described before (3), with the following modifications. 96-well ELISA plates (Maxisorp, Nunc) were coated with 100 µL of 1 µg/mL recombinant BMP9 or BMP10 (R&D Systems) in coating buffer (15 mM K2HPO4, 25 mM KH2PO4, 0.1 M NaCl2, 0.1 mM EDTA, 7.5 mM NaN3) and incubated overnight at 4 °C. Plates were then washed 3 times with 0.05% Tween PBS (PBST) and blocked for 1 h at room temperature (RT) with 1% BSA in PBS. After washing 3 times with PBST, serial dilutions of individual mouse serum samples and reference mouse anti-BMP9 and anti-BMP10 IgGs (R&D Systems) (diluted in 1% BSA PBS) were prepared and 100 µL/well were incubated for 2 h at RT. After 3 more washes, 100 µL/well horseradish peroxidase (HRP)conjugated goat anti-mouse secondary antibody (Southern Biotech, diluted 1:500 in 1% BSA PBS) was incubated for 1 h at room temperature. TMB substrate was added after 5 washes and the reaction was allowed to develop for 30 min at room temperature. The optical density was measured at 450 nm using a TECAN GENios Pro plate reader.
Blue latex dye injection. P9 pups were processed for cardiac perfusion after euthanasia, following procedures described before (3) . Briefly, the thorax and abdomen were opened. The left ventricles were injected manually with 600 µL of blue latex dye (BR80B, Connecticut Valley Biological Supply) using an insulin syringe U-100 (329652, BD Biosciences) and the right atrium was opened to drain the blood. After perfusion, liver, lungs, tongue, and palate were dissected, fixed in 4% paraformaldehyde (PFA), washed in phosphate-buffered saline (PBS) and either mounted in 80% glycerol (direct observation of the liver and lungs) or embedded in low gelling temperature agarose (A0701, Sigma) (tongue and palate). Blocks were dehydrated in methanol series and cleared with organic solvent (benzyl alcohol/benzyl benzoate, 1:1, Sigma). Images of the whole organ or tissue were acquired using an Olympus SZX7 stereomicroscope attached to an Olympus DP27 camera. Measurements and quantifications were performed using Fiji. For liver analysis, images from the same liver lobe and at the same location in the lobe were acquired at 1x magnification. The diameter of every hepatic vessel was measured at a distance of 2,000 µm from the margin of the lobe using the concentric circle tool plugin in Fiji. For the tongue and palate, images of the organs were acquired using 2x magnification and transversal lines were superimposed half-way in their anterior-posterior axis using the grid Fiji's plugin, where the vessel diameter was measured. For the lungs, images of lobes were acquired and main vessels' diameter was measured.
IHC.
To analyze the retinal vasculature, eyes were enucleated and fixed in 4% PFA for 20 min on ice and retinas were isolated and analyzed as before (3, 4) . Briefly, retinas were dissected, cut four times to flatten them into a petal flower shapes, and fixed with methanol for 20 min on ice. After removing methanol, retinas were washed in PBS for 5 min on a shaker at room temperature, and blocked in blocking solution (0.3% Triton, 0.2% BSA in PBS) for 1 h on a shaker at room temperature. Retinas were then incubated in Alexa Fluor 488 isolectin B4 (I21411, Molecular Probes) and/or primary antibodies in blocking solution on a shaker overnight at 4°C. Retinas were then washed four times in 0.3% Triton in PBS for 10 min on a shaker, incubated with the corresponding secondary antibodies, washed four times in 0.3% Triton in PBS for 10 min followed by two washes in PBS for 5 min on a shaker and mounted in Vectashield (H-1000, Vector Laboratories). Liver, heart, and spleen were fixed in 4% PFA for 24 h and sent for sectioning, H&E staining, and anti-HIF-1α IHC at HistoWiz. Unstained liver sections were dewaxed and antigen retrieval was performed. Sections (5 µm) were then washed in PBS for 5 min on a shaker at room temperature, and blocked in blocking solution (0.3% Triton, 0.2% BSA in PBS) for 1 h in a humid chamber at room temperature. Immunostaining was performed using primary antibodies in blocking solution in a humid chamber overnight at 4°C. Sections were then washed four times in 0.3% Triton in PBS for 10 min, incubated with the corresponding secondary antibody, washed four times in 0.3% Triton in PBS for 10 min followed by one incubation with DAPI (KPL 710300) in PBS and two washes in PBS for 5 min on a shaker before being mounted in Vectashield.
High resolution images for vascular network analysis were acquired using a Zeiss 880 laser confocal microscope. In cases where low magnification was enough for the analyses, an automated EVOS FL Auto 2 Invitrogen microscope was used. Measurements, quantifications, and 3D analysis were performed using Fiji. Briefly, low magnification images were acquired using a 4x and 10x lens to measure the retina vascular length (percentage of vasculature/retina length). A 20x lens was used to acquire images at the optic nerve to quantify AVM number, and AVM and vein diameter, and at the vascular plexus (3-5 fields per retina, between an artery and a vein) to quantify the vascular density. All measurements and qualifications were done using Fiji. The vascular density quantification was done by using the measure particles tool, working with 8-bit images, adjusting the threshold, and measuring the area occupied by the vasculature in a region of interest of 200 x 200 µm 2 . The bleeding area quantification was performed on 3 by 3 tiled image stacks using a 10x lens, and the 3D analysis by using the 3D project and the orthogonal view tools. Quantification of p-S6, p-VEGFR2, and p-Smad1/5/8 was performed by acquiring higher magnifications images using a 63x lens, analyzing 2 to 5 fields per retina and calculating the percentage of retinal vascular area occupied by immunostaining.
CBC. Blood samples from tBMP9/10ib mice were obtained through heart puncture using a 0.3 mL insulin syringe (324910, BD Biosciences). Blood was transferred to a tube containing 5 mM EDTA
